Fri, January 17, 2025
Thu, January 16, 2025
Wed, January 15, 2025
Tue, January 14, 2025
Mon, January 13, 2025
[ Mon, Jan 13th ] - NASA
Earth Science at Work
Sun, January 12, 2025
Sat, January 11, 2025
Fri, January 10, 2025
Thu, January 9, 2025
[ Thu, Jan 09th ] - Mashable
The best of CES 2025
Wed, January 8, 2025
Tue, January 7, 2025
[ Tue, Jan 07th ] - Indiatimes
Here are trends in GCCs
Mon, January 6, 2025

Seattle biotech startup Tune Therapeutics lands $175M to support clinical research


//science-technology.news-articles.net/content/2 .. ics-lands-175m-to-support-clinical-research.html
Published in Science and Technology on by MSN   Print publication without navigation

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Tune Therapeutics, a Seattle-based biotech startup, has successfully raised $175 million in a Series B funding round to advance its clinical research. The company focuses on developing treatments for genetic diseases using its proprietary genome editing technology, known as TEMPO (Targeted Epigenetic Modulation and Programming). This technology allows for precise, programmable control over gene expression without altering the underlying DNA sequence, offering potential treatments for conditions like chronic pain, autoimmune diseases, and various genetic disorders. The funding will support the expansion of Tune's research and development efforts, including the progression of its lead programs into clinical trials. The investment round was led by prominent venture capital firms, highlighting the growing interest and confidence in Tune's innovative approach to gene therapy.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/seattle-biotech-startup-tune-therapeutics-lands-175m-to-support-clinical-research/ar-BB1rkHtA ]

Publication Contributing Sources